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Introduction
Insulin is released from the pancreatic b-cells postprandially, signalling the fed state and directly stimulating glucose disposal into peripheral insulin target tissues as well as suppressing hepatic glucose output (HGO). Interference with any of these actions of insulin (i.e. impairment of insulin sensitivity at a peripheral or hepatic level) will tend to have a blood glucose elevating e¡ect. At an early stage in the pathophysiological process, this may be compensated for by an increase in bcell insulin output which maintains normoglycaemia. When the insulin secretion is no longer su⁄cient to maintain normoglycaemia then hyperglycaemia and diabetes develop.
Insulin resistance is a reduced ability of the hormone insulin to exert its biological e¡ects on target tissues -namely adipose tissue, skeletal muscle and liver. In terms of the blood glucose concentration, it can be de¢ned as a situation where the insulin concentration is inappropriately high for the level of glycaemia. It is important to understand at the outset that insulin sensitivity is a continuous variable. Thus young, lean, physically ¢t individuals are likely to be highly insulin sensitive whereas obese subjects with type 2 diabetes will have poor insulin sensitivity. Likewise, insulin resistance, the reciprocal of insulin sensitivity, is a continuous variable. This makes it di⁄cult to de¢ne cut-o¡ levels for insulin resistance and, rather than attempting to label individuals as 'insulin resistant' or 'insulin sensitive', it is more appropriate to consider each individual as lying somewhere along the continuum between very high and very low insulin sensitivity. This concept should be borne in mind when considering techniques used to assess insulin sensitivity.
The common form of insulin resistance is associated with increased waist circumference (visceral adiposity), hypertension, hyperglycaemia and dyslipidaemia involving a decreased serum HDL cholesterol concentration and a preponderence of small dense low density lipoprotein particles. 1, 2 A hypercoaguable state is often present, as well as increased in£ammatory cytokine levels. 3 These are also all features of the metabolic syndrome, a common condition associated with increased cardiovascular risk and increased risk of diabetes. 4 Although the link between obesity and insulin resistance is well established, insulin resistance may be present in non-obese and non-diabetic individuals along with other components of the metabolic syndrome or polycystic ovary syndrome (PCOS). 5--7 While this review focuses on biochemical tests used in the assessment of insulin sensitivity, it should be remembered that the likely presence of insulin resistance may be inferred from clinical features (e.g. the features of metabolic syndrome listed above, acanthosis nigricans, patients on high-dose corticosteroids or a requirement for a high insulin dosage to achieve normoglycaemia). Treatment with glucocorticoid analogues can induce an insulin-resistant state as cortisol is an anti-insulin hormone. 8 The molecular basis of insulin resistance Insulin resistance in its most common form is believed to have both genetic and environmental components ( Table 1 ). Its inheritance is polygenic, involving a wide variety of di¡erent genes. Many candidate genes have been investigated but the sites of the defects are not known in most cases. Variants of two genes encoding proteins in the insulin signalling pathway have been implicated, namely insulin receptor substrate-1, phosphatidylinositol 3-kinase and also the b 3 -adrenergic receptor. 28--30 Such inherited defects require additional defects in b-cell function if they are to lead to diabetes. Considerably more is known about the molecular basis of insulin resistance acquired due to environmental factors. For example, the insulin-responsive glucose transporter has been noted to be downregulated in adipose tissue in obese human subjects with insulin resistance and while expressed at normal levels in skeletal muscle in these subjects, its translocation to the cell surface is impaired. 31 Defects have also been observed in the subsequent oxidation of glucose and glycogen synthesis. Chronically elevated serum concentrations of non-esteri¢ed fatty acids (NEFA) present in obese subjects can inhibit peripheral glucose disposal, enhance HGO and impair b-cell function. 32 There is now considerable evidence supporting the fetal origins hypothesis (i.e. that factors at work in the fetal environment can predispose to insulin resistance and its sequelae in adult life). 33 The common form of insulin resistance discussed above should not be confused with extreme insulin resistance, which is a rare phenomenon and mentioned only brie£y for completeness. 34 It has a very di¡erent pathophysiological basis from ordinary insulin resistance. A number of syndromes have been described, including type-A insulin resistance due to inborn insulin receptor (I-R) defects, type-B insulin resistance due to the presence of anti I-R autoantibodies and type-C insulin resistance caused by post-binding defects in insulin signalling. Typically, patients with extreme insulin resistance have very high fasting insulin concentrations, 4300 pmol/L or 42000 pmol/L postprandially, the insulin concentration only being valid in this assessment if there is normoglycaemia. The patient may also have clinical features indicative of a recognized syndrome.
The value of assessing insulin sensitivity
The value of quantitative assessment of insulin sensitivity in clinical as opposed to research contexts is unclear at present. However, potential clinical utility for markers of insulin resistance can be envisaged. In the case of cardiovascular disease and diabetes, it would be advantageous to detect those at risk at an early stage in the process, prior to the derangement of other parameters and when intervention may interrupt the course of events leading to these diseases. It is Table 1 Causes of insulin resistance
Congenital factors
Fetal undernutrition 9 Ethnic differences 10 
Molecular defects (genetics)
Insulin receptor mutations (Type-A insulin resistance) 11 Post-binding signalling mutations (Type-C insulin resistance) 12 
Acquired factors
Physiological: Pregnancy, 13 puberty, 14 high fat diet, 15 physical inactivity, 16 aging 17 Hormonal:
Corticosteroids, 18 acromegaly, 19 phaeochromocytoma, 20 PCOS 21 Others:
Hypertension, 22 liver cirrhosis, 23 sepsis, 24 surgery, 25 burns and trauma, 26 useful to the clinician to have objective measures of improvement in response to medical intervention or lifestyle change. The presence of insulin resistance as indicated by a biochemical marker could prompt a more aggressive approach to risk reduction on the part of the clinician. In type 2 diabetes, the objective demonstration of insulin resistance may be useful in choosing the most appropriate oral hypoglycaemic agent. If insulin sensitivity is to be assessed in clinical contexts, this will necessitate the availability of a marker which has su⁄cient diagnostic e⁄ciency as well as being simple and inexpensive to measure.
Assessment of insulin sensitivity
A variety of methods are available for assessing insulin sensitivity, the choice of test depending on the purposes of the investigator (clinical or research), available resources (research sta¡ expertise, equipment, funds) and the information required (insulin sensitivity alone or information on b-cell function). The available methods can be divided into dynamic tests where specimens are collected serially and biochemical markers measured on a single specimen. They will be discussed separately. Key features of the tests available are summarized in Table 2 . 
Dynamic function tests

Hyperinsulinaemic euglycaemic clamp
The hyperinsulinaemic euglycaemic clamp is rarely performed in clinical care, but used mainly for medical research purposes, for example to assess the e⁄cacy of new medications. First described by DeFronzo et al. 48 in 1979, it remains the gold standard for investigating and quantifying insulin sensitivity in vivo in man. As its name suggests, it involves infusing exogenous insulin, usually at a constant rate of 6 mU/kg/min. This is given along with 20% glucose at a variable rate su⁄cient to maintain blood glucose concentrations between 5 and 5.5 mmol/L, the rate of the glucose infusion being determined by blood glucose monitoring at 5 min intervals. 49 The infused insulin suppresses HGO. This means that once a steady state is reached (usually during the last 30--60 min of the test) the rate of glucose infusion equals the rate of peripheral glucose disposal or the metabolic clearance rate. Individuals who are highly insulin sensitive require considerable exogenous glucose to maintain euglycaemia, whereas those who have insulin resistance require minimal exogenous glucose. The insulin-mediated glucose disposal rate is denoted by the metabolic clearance rate or M value; a high M value (47.5 mg/kg/min) indicates that the patient is insulin-sensitive and a low one (o4.0 mg/ kg/min) that the body is relatively resistant to insulin action. Levels between 4.0 and 7.5 mg/kg/min are not de¢nitive and suggest a pre-diabetic state. The value of M can be normalized to the fat free body mass or resting energy expenditure. The insulin sensitivity index (S I(clamp) ) is another parameter that authors have derived from the test data for the purpose of comparing clamp studies with the minimal model. It expresses the change in glucose clearance per unit change in plasma insulin concentration. For a full discussion of these parameters and details of their calculation, readers are directed to appropriate references. 49, 50 A list of parameters and reference limits is given in Ferrannini and Mari. 35 It can be seen that during the steady-state period, blood glucose and insulin concentrations of normal subjects are lower than those of obese subjects and those with diabetes. 44 
Hyperglycaemic clamp
The hyperglycaemic clamp is used primarily as a quantitative procedure to assess b-cell insulin secretion in response to glucose. Investigation of insulin secretory responses is of potential value in studying pre-diabetic states and the e⁄cacy of medications. 51 The plasma glucose concentration is acutely raised to a plateau 7 mmol/L above basal levels by means of a priming dose of glucose, and maintained at that level for 2 h, being monitored throughout as for the hyperinsulinaemic euglycaemic clamp. Following the priming dose, glucose is administered as maintenance doses at 5 min intervals until the end of the study. Hyperglycaemia stimulates b-cell insulin secretion which in turn enhances glucose disposal. The volumes of the maintenance doses required to maintain hyperglycaemia, therefore, provide an indication of insulin secretion.
As the glucose concentration in plasma is held constant, its infusion rate M (mg/kg/min) in addition provides an index of glucose metabolism. An M/I index can be calculated, where I is the average insulin concentration during the test. This index provides a measure of sensitivity to endogenously secreted insulin.
While they provide very valuable information, both hyperinsulinaemic euglycaemic and hyperglycaemic clamp techniques have notable limitations. They are demanding, laborious, time consuming, expensive, and not suitable for screening large populations. Moreover, they are performed under non-physiological conditions as glucose is administered intravenously, thus bypassing the e¡ect of the gastrointestinal tract on glucose absorption and insulin secretion.
Insulin tolerance test
First described in 1929, the insulin tolerance test (ITT) is the oldest method of assessing insulin sensitivity. 52 Unlike the clamp techniques, it estimates the net e¡ects of insulin on liver and peripheral tissues. 53, 54 It follows glucose disposal following an intravenous bolus of soluble insulin (0.1 U/kg). Blood samples are collected 15 and 5 min prior to injection and at 3, 6, 9, 12, 15, 20 and 30 min thereafter. At 30 min glucose is injected to stop a continuing fall in blood glucose. The rate of glucose disappearance constant (k ITT ) is then calculated as the slope of the decline in blood glucose plotted logarithmically. This parameter has been reported to be closely correlated with both insulin sensitivity measurements made by hyperinsulinaemic euglycaemic clamp (r ¼ 0.811; Po0.001) and measurements of b-cell glucose sensitivity made by the hyperglycaemic clamp (r ¼ 0.826; Po0.001). 36 However, as with clamping techniques, the ITT has its limitations. Importantly, it cannot provide information on the site of the defect in insulin action; that is, it cannot distinguish between reduced suppression of HGO and impaired peripheral glucose disposal. The test is arti¢cial in that the insulin concentrations attained are supraphysiological. The insulin can cause hypoglycaemia, which is unpleasant and potentially hazardous for the subject. 56, 49 For completeness it should be stated that other protocols have been used which involve di¡erences in the administered glucose load. Another short infusion protocol uses 25% glucose (0.3 g/kg) given as a bolus over 1min and a long infusion protocol 25% glucose (0.5 g/kg) over 3.5--4.5 min. 57, 58 Plasma glucose and insulin concentrations measured during the test are subjected to minimal model analysis. This is a mathematical representation of glucose kinetics during the FSIVGTT. The model describes glucose disposal using two di¡erential equations, one representing glucose kinetics and assuming a single compartment and the second describing the e¡ect of insulin assumed to take place in a compartment outside plasma. It predicts plasma glucose values at di¡erent times from the measured insulin values according to preset parameters. The minimum di¡erence between the measured glucose and the parameters represents the predicted values. Computer software is available for the analysis from which both insulin sensitivity (Si) and glucose e¡ectiveness (Sg) indices can be determined 56 (Table 3 ). Si re£ects the ability of insulin to promote peripheral glucose uptake and suppress HGO, whereas Sg is a measure of the e¡ect of glucose to enhance its own disposal under basal insulin concentrations. Si and Sg average 5 Â10 À4 /min/mU/mL and 0.021min À1 , respectively, in normal subjects. 65, 66 These are concordant with analogous parameters in the hyperinsulinaemic euglycaemic clamp. A number of other parameters can be derived including the acute insulin response . A full list of parameters and reference ranges is given in Boston et al. 60 
Modified FSIVGTT
Although parameters derived from minimal model analysis correlate with those from clamp studies, the correlation is weaker in patients with type 2 diabetes, because these patients have poorer insulin responses. This requirement for a detectable and consistent insulin response means that use of the standard FSIVGTT is limited in subjects with diabetes. In an e¡ort to overcome this problem, the test has been modi¢ed to enhance the insulin response. The ¢rst approach to this was by the administration of a dose of the sulphonylurea drug tolbutamide (4.3 mg/kg) to ensure that subjects with type 2 diabetes have an adequate second-phase endogenous insulin response. 67 This approach was later superseded by the insulin-modi¢ed FSIVGTT in which insulin itself is infused in order to supplement the endogenous insulin response. 68 An intravenous dose of insulin (30mU/kg) is given 20 min into the test, additional blood samples being taken at 23, 24 and 27 min. This is now the most popular protocol as it allows better estimation of the Si index. 67 A study comparing parameters calculated from this version of the FSIVGTT and the hyperinsulinaemic euglycaemic clamp showed the values to be signi¢cantly correlated in the group as a whole (r ¼ 0.62, Po0.001), as well as in subjects with normal glucose tolerance (r ¼ 0.53, P ¼ 0.048), impaired glucose tolerance (IGT) (r ¼ 0.48, P ¼ 0.016) and type 2 diabetes (r ¼ 0.41, P ¼ 0.030). 39 In an e¡ort to make the test less labour intensive, researchers have investigated the use of protocols requiring fewer samples. It has been shown that in non-diabetic subjects a reduced sampling schedule yields similar results to those obtained using the original protocol, the simpli¢ed technique requiring 12 samples instead of 25. 38 A study comparing a reduced sampling protocol for the insulin-modi¢ed FSIVGTT with the glucose clamp showed parameters to be modestly correlated in the group as a whole (r ¼ 0.55, Po0.001), as well as in the normal glucose tolerance (r ¼ 0.53, P ¼ 0.046), and IGT groups (r ¼ 0.58, P ¼ 0.008), but not in those subjects with type 2 diabetes (r ¼ 0.30, P ¼ 0.085). 39 This suggests that the full sampling protocol is preferable where subjects with diabetes are to be investigated. The limitations of the FSIVGTT are its time-consuming nature, requiring 3--4 h altogether, and that analysis of the data is dependent on availability of the appropriate software.
Oral glucose tolerance test
Alternative methods have been sought in order to simplify the measurement of insulin sensitivity, a number of which involve deriving indices from data obtained during the oral glucose tolerance test (GTT). During the GTT, a fasted subject takes a 75 g oral dose of glucose dissolved in water. Blood glucose concentrations are then measured over the following 2 h. The GTT is commonly carried out in clinical practice for the purpose of classifying patients according to their glycaemic status (i.e. normal, impaired fasting glucose [IFG], IGT or diabetic), the glucose result being interpreted according to World Health Organization (WHO) criteria. 69 For this purpose, a fasting and 2 h plasma glucose concentration are su⁄cient. However, for the purposes of research, the glucose concentration may be measured at more frequent intervals. When this is done, the glucose concentration in normal subjects is observed to peak after 30--60 min and return to baseline after 2 h. In subjects with diabetes, the glucose curve is both elevated and delayed, an early elevation re£ecting loss of the post-prandial peak in insulin production. When the impairment of insulin sensitivity is at an early stage, the GTT may be normal or only mildly abnormal.
By measuring insulin and glucose concentrations at multiple time points in a GTT, various parameters of interest can be derived. An index of whole-body insulin sensitivity, ISI (composite), has been observed to be well correlated with insulin sensitivity measurements made using the hyperinsulinaemic euglycaemic clamp (r ¼ 0.73, Po0.0001). 40 It is calculated as follows: 10000 p ½fasting glucose ðmg=dLÞ Â fasting insulin ðmU=mLÞ Â½mean glucose Â mean insulin This index has an advantage that it takes account of both hepatic and peripheral insulin sensitivity, providing a more comprehensive assessment of the individual. Indices which assess only one or the other are limited because they do not take account of the observation that hepatic and peripheral insulin sensitivity may a¡ected to di¡erent extents in individuals owing to di¡erent metabolic abnormalities. Hence the di¡erent responses that can be obtained during the GTT (i.e. elevated fasting plasma glucose concentration or elevated 2 h plasma glucose concentration).
The insulin sensitivity index-glycaemia (ISI-gly) is calculated from plasma glucose and insulin concentrations measured at baseline and post oral glucose load. 70, 41 As a result, it provides a more accurate estimate of whole-body insulin sensitivity than the homeostasis model assessment-insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) indices, discussed below, which are derived from fasting values alone. 71 ISI-gly re£ects peripheral insulin sensitivity, while the other two indices re£ect hepatic insulin sensitivity. It is a more sensitive method for detecting insulin resistance in the context of metabolic abnormalities and cardiovascular disease and has been shown to correlate inversely with age and body mass index (BMI). A meta-analysis of data from di¡erent studies showed a signi¢cant correlation between ISI-gly and measurements of insulin sensitivity made by the hyperinsulinaemic euglycaemic clamp technique. 41 The index is calculated as follows:
where insulin p and glucose p represent the sum of measurements of insulin (mU/mL) and glucose (mg/dL), taken before and 2 h after a standard 75 g oral glucose load, divided by the sum of their respective normal values. The lower the ISI-gly value, the lower the insulin sensitivity. Normal subjects have a value around 1, with 0 and 2 being the minimum and maximum possible values, respectively. Although data from studies such as the above suggests that indices have the potential to sensitively detect insulin resistance, clinical guidelines do not as yet recommend the use of fasting insulin or indices in screening for insulin resistance. 72 The ratio of change in insulin to change in glucose over the ¢rst 30 min of a GTT (D30 min insulin/ D30 min glucose) is a measure of insulin secretion and has been observed to predict the development of type 2 diabetes. 73 Stumvoll et al. 74 studied insulin release and insulin sensitivity in non-diabetic volunteers using hyperglycaemic and hyperinsulinaemic euglycaemic clamps. The same individuals then underwent a GTT and equations were derived which predicted insulin sensitivity index and ¢rst and second phase insulin secretion. The parameters predicted by these equations correlated better with measured parameters than with D30 min insulin/D30 min glucose or with HOMA-IR. The equations predicting insulin sensitivity index and metabolic clearance rate take BMI, 120 min plasma insulin concentration and 90 min plasma glucose concentration into account. These may be used in epidemiological studies where the clamp technique is impractical but a GTT is considered appropriate.
The GTT has considerable limitations both in the assessment of glycaemic status and insulin sensitivity. Gastrointestinal delivery of the glucose load means that results can be in£uenced by di¡erent rates of gastric emptying as well as by post-absorptive glucose handling. There is large intraindividual variation in the test, hence the WHO recommendation that before diagnosing diabetes, patients should have levels within the diagnostic range for diabetes on more than one occasion. It should also be noted that although a wide variety of indices for insulin resistance and b-cell function have been derived from the GTT, not all have been rigorously validated against the gold standard.
Continuous infusion of glucose with model assessment
Continuous infusion of glucose with model assessment (CIGMA) is a mathematical model which assesses endogenous insulin secretion and b-cell function in response to infusion of glucose at a constant rate (5 mg/kg/min for 60 min). Blood samples are collected at 50, 55 and 60 min for glucose and insulin measurement at which time the subject will be in near steady state. Assessment of insulin resistance using CIGMA was observed to correlate well with measurements made by hyperinsulinaemic euglycaemic clamp (r ¼ 0.87, Po0.0001). The b-cell function measured by CIGMA correlated closely with steady-state plasma insulin concentrations during hyperglycaemic clamp (r ¼ 0.64, Po0.002. 75 CIGMA su¡ers from the same limitations as HOMA-IR discussed below. Its interpretation is dependent on a model.
Stable isotope techniques
Stable isotope tracers have been extensively used in the study of carbohydrate and fat metabolism at a whole body level. 76 Apart from the obvious safety considera-tions, this methodology o¡ers a number of advantages over the use of radioactive tracers. The location of the label within a molecule can be determined using selected ion monitoring gas chromatography (GC)mass spectrometry (SIM-GC-MS), which minimizes problems due to recycling of the label, and multiplelabelled molecules can be used, increasing the complexity of information obtained. In the determination of insulin sensitivity, stable isotopes have most frequently been used in the context of the FSIVGTT, the combined technique ¢rst described in 1991. 42 The purpose of using the label is to distinguish endogenous glucose production from peripheral glucose disposal. Its use also increases the precision of measurement of the parameters compared with those measured by the standard FSIVGTT. An intravenous bolus of tracer is given along with the main glucose bolus and followed by GC-MS, the most widely used tracer being [6,6-2 H 2 ]glucose. This method has, for example, been used in studying di¡erences in insulin sensitivity and glucose metabolism in pregnant women with or without gestational diabetes. 77 One problem with this tracer, however, is the expense incurred by the relatively large doses required (about 2 g) to achieve measurable concentrations. More recently [1-13 C]-glucose has been proposed as an alternative. 78 While the parameters obtained are similar to those obtained using deuterated glucose, the use of this isotope gives greater analytical precision and sensitivity. This allows reduction in the 82 Reprinted with permission from The American Diabetes Association size of dose administered (about 120 mg), giving a cost advantage. 79 Recently a protocol has been described whereby a dose of [1-13 C]-glucose is given intravenously following an oral glucose load and serial sampling then carried out as in the FSIVGTT. 80 The authors called this an 'orally stimulated intravenous glucose tolerance test' as it combines the advantages of obtaining physiological stimulation of insulin secretion by mimicking a meal while at the same time avoiding the need to consider kinetics of gastrointestinal glucose absorption by simply following the disappearance of the intravenously administered label. The indices of insulin sensitivity were reported to be 2--3 times higher than those obtained using the standard FSIVGTT and were highly reproducible. Stable isotopes of glucose have also been used in combination with clamp techniques to permit researchers to accurately quantitate endogenous glucose production. For example, the administration of [6,6-2 H 2 ]-glucose during a hyperinsulinaemic euglycaemic clamp procedure allowed researchers to study the e¡ects of short-term dietary change on glucose dynamics in subjects with type 2 diabetes. 81 
Biochemical markers on a single specimen
While clamp studies and other dynamic techniques can provide valuable information on insulin sensitivity, they are invasive, technically demanding procedures and not suited to the study of large populations. There is a need for biochemical markers which are straightforward to measure and that will provide useful information when measured on a single specimen. Interest has therefore developed in markers that correlate with insulin sensitivity and so might ful¢l this role. Inevitably these tests, like all biochemical markers, have their limitations and will tend to misclassify some patients. As with all biochemical tests, their results should not be considered in isolation but in the context of clinical ¢ndings and results of other investigations.
Homeostasis model assessment
HOMA is a method used to quantitate insulin resistance, ¢rst described in 1985. 43 This is based upon the principle that the degree of fasting hyperglycaemia is determined by a combination of b-cell de¢ciency and insulin resistance. Any given combination of insulin sensitivity and b-cell dysfunction will be associated with characteristic glucose and insulin concentrations during the fasting state. The authors used a computersolved mathematical model of fasting insulin and glucose interactions to plot an array of fasting plasma insulin and glucose concentrations expected for di¡er-ent degrees of insulin resistance and b-cell de¢ciency. This model was later updated using non-linear solutions ( Figure 1) and this is the version that should now be used when comparing HOMA to other models. 82 The chart can be used to estimate the insulin sensitivity (HOMA-%S) which is the inverse of insulin resistance (HOMA-IR), and b-cell function (HOMA-b%) expected from the measured fasting plasma insulin and glucose concentrations observed in an individual. Alternatively, insulin resistance values for a subject can be derived from fasting measurements as follows:
For glucose values reported in mg/dL, the equation becomes:
The HOMA-IR index correlates well with estimates of insulin sensitivity using the hyperinsulinaemic euglycaemic clamp (r ¼ 0.88, Po0.0001), the hyperglycaemic clamp (r ¼ 0.69, Po0.01) and the fasting insulin concentration (r ¼ 0.81, Po0.0001). 43 HOMA-b% is calculated as:
This index correlates with measurements of b-cell function derived using the hyperglycaemic clamp (r ¼ 0.61, Po0.01) and the FSIVGTT (r ¼ 0.64, Po0.05). 43 Clearly HOMA is more convenient for the subject than clamp techniques, but its precision is poor, with a 31% coe⁄cient of variation (CV) for HOMA-IR and 32% CV for HOMA-b. The authors recognized that this limits the usefulness of a single measurement in clinic, though the precision can be improved slightly by taking three measurements 5 min apart or by using a more speci¢c insulin assay. 43, 83 The sensitivity of the technique for detecting metabolic abnormalities is poor, as post-load insulin and glucose concentrations are not included in the calculation. As the HOMA-IR index is determined from results on fasting specimens, it essentially provides an estimation of hepatic insulin sensitivity. The homeostatic model therefore has the important limitation that it assumes hepatic and peripheral insulin sensitivity are equal, which in reality is not the case.
Since 1985, other modi¢cations have been made to the model to take account of the physiology more accurately. A computer programme which does this is available and makes more precise predictions. 84 Log transformed HOMA-IR [Ln(HOMA)] correlates well with clamp studies. 83 In a study comparing Ln(HOMA) and HOMA-IR with Si derived by MINMOD from FSIVGTT, Ln(HOMA) correlated more strongly than HOMA-IR in subjects with normal glucose tolerance, IGT and type 2 diabetes. The authors advocated Ln(HOMA) as a better predictor of insulin sensitivity than HOMA-IR. 85 Despite their limitations, HOMA indices have been extensively used in population studies. In a 3.5 year follow-up study, HOMA-IR was shown to strongly predict the development of type 2 diabetes and was a better predictor than fasting insulin alone. 86 A decreased HOMA-b% did not predict the development of diabetes.
Quantitative insulin sensitivity check index
QUICKI 44 is an index of insulin sensitivity calculated from glucose and insulin measurements made on a The lower the QUICKI value, the lower the insulin sensitivity. QUICKI has been correlated with measurements made by clamp techniques and FSIVGTT, showing a stronger correlation with the former. 44 This index is similar to HOMA, except that it interprets the data by taking both logarithms and the reciprocal of the fasting glucose-insulin product. Consequently, it is more accurate than HOMA in calculations over a broad range of insulin sensitivities. QUICKI has also been used in large population studies.When applied to obese subjects in a ¢ve year prospective study, QUICKI was better able to predict the future development of type 2 diabetes than a fasting insulin concentration alone. 87 In a recent large study on Korean adults using QUICKI as a surrogate measure of insulin sensitivity, cut-o¡ levels were determined for the purpose of diagnosing metabolic syndrome. 88 Although QUICKI correlates well with the gold standard in patients with abnormal glucose tolerance and diabetes, the correlation is poorer in those with normal glucose tolerance (i.e. where insulin resistance is mild). This led researchers to propose the revised QUICKI which incorporates the level of fasting NEFA into the equation: 89 Revised QUICKI ¼ 1=½log insulin ðmU=mLÞ þ log glucose ðmg=dLÞ þ log NEFA ðmmol=LÞ
This improved the discriminatory power of the index, the revised QUICKI having been reported to correlate beter with the gold standard than the original index. 90 A study comparing a variety of insulin sensitivity indices with Si values determined by the FSIVGTT showed the revised QUICKI to correlate best with the minimal model. 91 QUICKI su¡ers from the same limitation as HOMA in that it does not take post-dose glucose and insulin concentrations into account. It is also di⁄cult to apply QUICKI to subjects with uncontrolled diabetes or who lack endogenous insulin secretion (i.e. subjects with type 1 diabetes).
Serum insulin
Since insulin resistance is a key feature of metabolic syndrome, 92 it would be anticipated that measurement of serum insulin concentrations alone might be of value in the assessment of insulin sensitivity. 13 C, and 31 P to measure non-invasively the concentration of intracellular metabolites and to assess biochemical differences between normal subjects and those with diabetes e.g. investigation of insulin-stimulated glycogen synthesis in skeletal muscle and identification of defects in glucose transport and metabolism 127
Positron emission tomography (PET)
An imaging technique which uses radiopharmaceuticals labelled with positron emitters. It permits non-invasive quantitation of glucose uptake into individual tissues such as skeletal and cardiac muscle Hyperinsulinaemia in the presence of normoglycaemia has been shown to provide evidence of insulin resistance. 93 Although there is considerable overlap in insulin concentrations between normal and insulin resistance, a fasting serum insulin concentration of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) has been considered a marker of insulin resistance. 94 Generally, a young, physically ¢t individual who is not overweight and with no glycaemic abnormalities would be expected to have a fasting insulin concentration below this. Cut-o¡ levels have been also suggested by the American Heart Association for the evaluation of fasting insulin concentrations in children. A value 420 mU/L (4120 pmol/L) in the face of normoglycaemia is stated to indicate a degree of hyperinsulinaemia and insulin resistance. 95 Fasting serum insulin measurements are widely used in clinical contexts for providing evidence of insulin resistance. Levels correlate with the components of the insulin resistance syndrome. 96 However, clinicians should be aware of the limitations of this approach. Insulin as a single biochemical marker can be misleading, as its concentration depends on b-cell reserves and insulin degradation as well as on insulin sensitivity. Early in the pathological process of insulin resistance, increased insulin secretion will occur; subsequently, as b-cell exhaustion occurs, insulin concentrations fall. This could be misinterpreted as being indicative of high insulin sensitivity, especially if a blood glucose concentration is not measured concomitantly. However, serum insulin concentrations only account for a small proportion of the variability in insulin action.
An important methodological limitation is that there is no standard method for insulin measurement and no standardization across laboratories. Thus there will be interlaboratory di¡erences in the values considered indicative of insulin resistance. In addition, proinsulin cross-reacts in many immunoassays. 97, 98 Reference ranges are not available for every insulin assay. If available, they would need to be age-and BMI-related ranges. In view of these de¢ciencies, it is inadvisable, in the context of insulin resistance, to use insulin concentrations alone for making treatment decisions in individual patients, except where extreme insulin resistance is present and concentrations are unequivocally elevated. The type of insulin assay used is clearly a factor that should be borne in mind in interpreting the results of the dynamic tests discussed above. In particular, care should be taken when comparing results of indices which have been derived from insulin concentrations obtained by di¡erent assays.
When combined as a ratio with fasting glucose, the insulin concentration may be more useful than in isolation. For example, the fasting glucose/insulin ratio (FGIR) has been compared with Si values determined by the FSIVGTT and suggested as a screening test for insu-lin resistance in women with PCOS. The authors suggested that this may be a useful parameter for selecting patients likely to respond to therapeutic interventions. 99 
Sex hormone-binding globulin
Sex hormone-binding globulin (SHBG) is an insulinregulated, liver-derived protein that has appeared promising in detecting individuals with hyperinsulinaemia. Clinical studies have shown an association between insulin resistance and SHBG concentrations. 100 Low plasma SHBG concentrations have been correlated with several components of the metabolic syndrome in both men and women and linked to cardiovascular risk (e.g. total and abdominal adiposity and hyperinsulinaemia, glucose intolerance and insulin resistance). 101--103 A study using the hyperinsulinaemic euglycaemic clamp technique showed SHBG concentrations to correlate signi¢cantly with insulin sensitivity in men (r ¼ 0.74; Po0.001). 46 Insulin-like growth factor binding protein-1
There are at least six insulin-like growth factor binding proteins (IGFBPs). Of these, IGFBP-1is mainly expressed in the liver, decidualized uterine endometrium, ovarian granulosa cells and kidney, and it is abundant in blood. 104 Its expresion is regulated by insulin, which inhibits transcription of the IGFBP-1 gene in liver. IGFBP-1 mRNA has a half-life of around 2 h, allowing up to a 10-fold increase in the blood concentration of the protein within a short period. 105 The serum IGFBP-1 concentration therefore varies reciprocally with the ambient insulin concentration. The serum half-life of IGFBP-1 has been reported at 89 min, considerably longer than that of insulin, which is only a few minutes. This means that serum IGFBP-1 concentrations lag behind insulin concentrations and may be useful to indirectly assess insulin secretion. 104 Hence patients who have hyperinsulinaemia for any reason would be expected to have low serum IGFBP-1 concentrations.
These observations have led to interest in IGFBP-1 as a possible marker of insulin resistance as it has the potential to identify patients with reduced insulin sensitivity by means of a simple fasting blood test. Low serum IGFBP-1 concentrations have indeed been shown to correlate with hyperinsulinaemia and to be associated with a variety of other cardiovascular risk factors (e.g. BMI, serum triglyceride and HDL-cholesterol concentrations, which are all features of the metabolic syndrome). 106 As well as predicting cardiovascular risk, the serum IGFBP-1 concentration was observed to increase in response to appropriate lifestyle interventions. 107 Following diet, exercise, or a combination of the two, fasting serum IGFBP-1 concentrations increased signi¢cantly. The greatest increase was observed with the combination of interventions where serum IGFBP-1 climbed from 33.7 to 42.6 ng/mL (Po0.001). Serum IGFBP-1 concentrations have also been observed to correlate strongly with M values obtained in the hyperinsulinaemic euglycaemic clamp, supporting the contention that it has a place in the clinical assessment of insulin sensitivity and assessment and monitoring of cardiovascular risk. 47 Fasting nondiabetic subjects with an M value of p5.0 mg/kg/min had serum IGFBP-1 concentrations of 6.270.91ng/mL (mean7SE) while subjects with an M value of 45 mg/kg/min had IGFBP-1 concentrations 15.9 ng/ mL (r ¼ 0.73, Po0.004). Using glucose-stimulated hyperinsulinaemia as a marker of insulin resistance, Saitoh et al. 108 compared this with fasting IGFBP-1 concentrations measured in prepubertal obese children and non-obese controls. Obese patients had fasting serum IGFBP-1 concentrations of 41.074.8 ng/mL (mean7SE) compared with 91.279.9 ng/mL in controls (Po0.005). Fasting serum IGFBP-1 concentrations correlated with the insulin response (r ¼ À0.7, Po0.005). These data support the contention that the fasting serum IGFBP-1 concentration may be useful as an early predictor of insulin resistance.
In comparison with SHBG, IGFBP-1 is a more sensitive marker of insulin sensitivity, its serum concentrations having been observed to decrease more than those of SHBG during hyperinsulinaemic clamps. 109 In addition, IGFBP-1 has the advantage over SHBG of being free from the e¡ects of confounding factors that in£uence SHBG concentrations (i.e. oestrogens and testosterone). 110 Although the information that such markers provide is relatively crude compared with information obtained from clamp studies, it may be suf-¢cient for clinical purposes. Further research is ongoing to try to identify simple robust surrogates of insulin resistance and such parameters should also be tested for their associations with clinical end points in prospective studies.
A variety of other biochemical markers namely hormones, enzymes, in£ammatory markers, coagulation factors, lipids and blood cell components, the serum concentrations of which have been noted to correlate with insulin resistance, are listed in Table 4 . Further information on insulin resistance can be obtained using the complementary techniques listed in Table 5 .
Conclusions
A wide variety of techniques are available for assessing insulin resistance all of which have their own advantages and limitations. Researchers and clinicians need to give careful consideration to the choice of test in order to be certain that it is adequate for their purpose. All tests continue to undergo further evaluation and re¢nement. In the future it is likely that modi¢cations to the gold standard will be able to provide ever more detailed and precise data for the purposes of the researcher and that simple biochemical tests will emerge for use in clinical contexts which can provide information of value in managing patients.
